The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial randomized 15,603 patients at high vascular risk to clopidogrel 75 mg/day or placebo for 28 months to determine if the drug reduces the rate and severity of stroke (Hankey et al. Stroke 2010; 41: 1679-1683). All patients also received ASA. Results have now been published on a prespecified substudy examining the functional severity of stroke outcomes, as assessed by the modified Rankin Scale (mRS) three months post-stroke.